Wheat aleurone is a novel wheat grain fraction with high levels of potentially healthpromoting compounds. New clinical trials with ready-to-eat cereals and bread containing wheat aleurone have been performed, and showed increased blood concentrations of tentatively beneficial compounds such as betaine, and decreased homocysteine and LDL-cholesterol which are both associated with heart disease risk.
It is important for the food industry to understand and to demonstrate the health benefits of foods, so that consumers can be offered foods with scientifically proven health benefits. This needs effective collaborations across the food chain, from growers to processors to food production, and further to the researchers who study the physiological responses and clinical outcome.
Buhler produced aleurone fractions in their pilot production plants in Switzerland, which were then incorporated into ready-to-eat cereal by Buhler, and into bread rolls by Barilla in Italy. These products contained 9 g aleurone per portion. The University of Ulster in Northern Ireland, UK conducted a 4-week randomised controlled clinical study with human subjects, who consumed two portions of bread rolls, and one portion of ready-to-eat cereal as part of their diets. The study showed that, compared to control products, the consumption of the products, which provided 27 g aleurone per day, led to significant changes in a number of plasma biomarkers. Betaine increased, and there were decreases in homocysteine and LDLcholesterol, which are both associated with heart disease risk. Furthermore, there was a decrease in C-reactive protein (CRP) which is a biomarker for inflammation.
The test foods were produced in collaboration with Walter von Reding and Caecilia Spöerndli from Buhler AG, and Roberto Ranieri and Giancarlo Riboldi from Barilla G. e R. Fratelli SpA.
Materials provided by VTT Technical Research Centre of Finland. Note: Content may be edited for style and length.
Cite This Page: